Search

A recent study conducted at Robert Bosch Hospital focused on the efficacy of sparsentan in treating IgA nephropathy in patients already receiving SGLT2 inhibitors. The study involved 23 patients with stable kidney function and protein levels, showing a significant reduction in proteinuria after 14 weeks of sparsentan treatment. The research suggests that sparsentan may have a positive impact on proteinuria in patients with IgA nephropathy, even when used in combination with SGLT2 inhibitors. [Extracted from the article]

A recent study from Monash University explores the functional crosstalk between Angiotensin Receptors (Types 1 and 2) and Relaxin Family Peptide Receptor 1 (Rxfp1), shedding light on how these cell surface receptors interact and influence each other's actions. The research suggests that these receptors can function as homodimers and heterodimers, impacting the function of each receptor. The study focuses on the implications of this interaction for fibrosis, a condition characterized by tissue scarring resulting from failed wound healing, which is often associated with chronic diseases and organ dysfunction. The findings have been published in the British Journal of Pharmacology and are available for further exploration. [Extracted from the article]

A study conducted by researchers at Brown University explored the relationship between the use of Angiotensin Receptor Blockers (ARBs) and the prevalence of adhesive capsulitis in patients. The study, which analyzed data from a large national insurance database, found that patients prescribed ARBs had lower rates of newly diagnosed adhesive capsulitis and required less surgical intervention compared to a control group. The findings suggest a potential protective effect of ARBs against the development of adhesive capsulitis, although further investigations are needed to understand the underlying mechanisms. The research was published in the Journal of Shoulder and Elbow Surgery and has been peer-reviewed. [Extracted from the article]

A recent study conducted at Lanzhou University in Gansu, China, explored the impact of using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the survival of hypertensive patients with cancer. The study found that patients with certain types of cancer who used ACEIs or ARBs had significantly increased survival times, except for those with breast cancer and uroepithelial carcinoma. The research suggests that further investigation into the mechanisms of action of these drugs could lead to novel therapeutic options and improve the prognosis of cancer patients in the future. [Extracted from the article]

Researchers at Nanjing Medical University in China have conducted a study on peptide receptors and their potential role in immune checkpoint blockade (ICB) therapy. The study found that angiotensin II receptor 1 (AGTR1), a target of angiotensin receptor blockers (ARBs), is overexpressed in armored and cold tumors and is associated with a poor response to ICB therapy. The researchers also discovered that ARBs can suppress the aggressiveness of tumor cells with high AGTR1 expression and enhance the efficacy of ICB therapy. These findings provide new insights into the treatment of refractory armored and cold tumors. [Extracted from the article]

A recent study conducted by researchers at Harvard Medical School has explored the potential of nanobodies, a type of antibody, in expanding the scope of angiotensin receptor pharmacology. The researchers developed nanobody antagonists against the angiotensin II type I receptor and found that they can bind to the receptor alongside specific small-molecule antagonists. This discovery suggests that nanobodies have the potential to be next-generation modulators of G-protein-coupled receptors. The study provides valuable insights into the properties and pharmacology of antibodies as GPCR ligands. [Extracted from the article]

A recent study conducted by researchers at the University of Arizona explored the effects of transient treatment with an Angiotensin II converting enzyme inhibitor (ACEi) and an Angiotensin II receptor antagonist (ARB) on oxidative stress and fibrotic signaling in the hearts of spontaneously hypertensive rats. The study found that both ACEi and ARB treatments showed long-term beneficial effects on oxidative stress. However, ARB treatment appeared to sensitize both male and female rats to a hypertrophy response to Angiotensin II. The study suggests that further research is needed to understand the mechanisms behind these differential responses and their implications for cardiac fibrosis. [Extracted from the article]

Researchers from the National Institutes of Health (NIH) have conducted a study on nanobodies and their potential as dualsteric ligands for the angiotensin II type 1 receptor (AT1R). Dualsteric ligands consist of an orthosteric pharmacophore and an allosteric pharmacophore, allowing them to display characteristics of both orthosteric and allosteric ligands. The researchers found that nanobody-mediated interactions with the receptor can enhance the potency, modulate the maximal effect, or alter the bias of angiotensin analogs. This study provides insights into the potential of nanobodies as allosteric reagents for drug development. [Extracted from the article]

A recent study conducted by researchers from the Center for Innovation Quality Effectiveness & Safety explores the prescribing practices and patient experiences with renin angiotensin system inhibitors (ACEIs/ARBs) in veterans with chronic kidney disease (CKD). The study found that ACEIs/ARBs are underutilized in patients with CKD, and little is known about the reasons for discontinuation and lack of reinitiating these medications. The researchers interviewed clinicians and patients and identified key areas for improvement, including patient education, knowledge gaps, and the development of a decision support tool to facilitate prescribing and management of ACEIs/ARBs. The findings will inform the development of such a tool to improve long-term outcomes in high-risk patients. [Extracted from the article]

A study conducted at Massachusetts General Hospital examined the effects of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the response to angiotensin II treatment in vasodilatory shock. The study found that patients who were previously exposed to ACEi showed increased responsiveness to angiotensin II, while those exposed to ARB showed decreased responsiveness. These findings have implications for patient selection and dosage of angiotensin II in the treatment of vasodilatory shock. The study was supported by the La Jolla Pharmaceutical Company. [Extracted from the article]

A recent study aimed to explore the potential interaction between the drug sparsentan and the angiotensin II type-2 receptor (AT2R). Sparsentan is an antagonist of angiotensin II and has been approved by the FDA for its efficacy in treating proteinuria. The study used molecular docking simulations to predict the binding conformation between sparsentan and AT2R. The results suggest that sparsentan may potentially interact with AT2R, providing valuable information for understanding its mechanism of action and guiding the design of AT2R-targeted drugs. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

Mineralys Therapeutics Inc. has filed a patent application for a method of treating low renin hypertension, a form of hypertension characterized by low levels of plasma-renin concentration or low plasma-renin activity. The method involves administering a CYP 11b2 beta hydroxylase inhibitor to these patients. The patent application describes various compounds and salts that can be used as inhibitors, as well as specific dosages and administration schedules. The inhibitors aim to suppress aldosterone production, increase potassium levels, and increase plasma renin activity in low renin hypertensive patients, without significantly reducing cortisol levels or causing an accumulation of 11-deoxycortisterone. [Extracted from the article]

A recent study conducted by researchers at Lovely Professional University focused on the potential therapeutic effects of Rauwolfia serpentina in managing hypertension. The study utilized molecular docking simulations to investigate the molecular interactions between the chemical constituents of Rauwolfia serpentina and key hypertensive targets. The results showed significant binding affinities between the compounds and the target proteins, suggesting their potential as novel therapeutic agents for hypertension management. Further in vitro and in vivo studies are recommended to explore these findings. This research provides valuable insights into the molecular mechanisms underlying the antihypertensive effects of Rauwolfia serpentina. [Extracted from the article]

A recent study conducted at the University Gadjah Mada in Indonesia investigated the association between antihypertensive drug classes and the risk of post-stroke cognitive impairment (PSCI) among first-ever ischemic stroke patients. The researchers analyzed data from a medical database and found that 71.11% of patients developed PSCI at 90 days after stroke. The study revealed that angiotensin receptor blockers (ARB) reduced the risk of PSCI by 64% and improved cognitive performance. These findings may assist clinicians in selecting antihypertensive drug classes for PSCI prevention. [Extracted from the article]

A study conducted at Taipei Veterans General Hospital in Taiwan examined the association between the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) and the risk of acute kidney injury (AKI) in critically ill patients. The study included 952 dialysis-free patients admitted to intensive care units between 2015 and 2017, with 476 of them being long-term ACEi/ARB users. The results showed that ACEi/ARB users were not associated with an increased risk of AKI during hospitalization compared to non-users. However, subgroup analysis revealed that ACEi/ARB users with sepsis or hypotension had an increased risk of AKI. Additionally, ACEi/ARB users had a lower incidence of mortality or dialysis within one year compared to non-users. The researchers concluded that further large-scale studies are needed to confirm these findings. [Extracted from the article]

A study conducted by Oregon Health & Science University (OHSU) investigated the use of angiotensin receptor blockade (ARB) in combination with stereotactic body radiation therapy (SBRT) for early stage lung cancer. The study found that patients taking ARBs during SBRT exhibited improved overall survival (OS) and recurrence-free survival (RFS) compared to patients not taking ARBs. However, the same effects were not observed in patients taking angiotensin converting enzyme inhibitors (ACEIs) or statins. These findings suggest that ARB use during SBRT may be beneficial for patients with early stage lung cancer. [Extracted from the article]

A recent study conducted by researchers at Universitas Padjadjaran in Bandung, Indonesia, has found that the use of losartan, an angiotensin II receptor blocker, can reduce fibrosis in the corpora cavernosa, which is associated with priapism and erectile dysfunction. The study involved male Wistar rats and evaluated the effects of losartan on the expression of Transforming Growth Factor-b1 (TGF-b1) and collagen-type-1 in cavernous tissue. The results showed that losartan significantly decreased collagen-type-1 deposition and improved tissue regeneration. This research suggests that losartan therapy may be beneficial in preventing fibrosis in priapism. [Extracted from the article]

A recent report from Ben-Gurion University of the Negev discusses new findings on the use of tetrahydrocannabinol (THC) for neuroinflammation treatment. The study focuses on the combination of cannabidiol (CBD) and angiotensin receptor blockers (ARBs) in inhibiting glial nitric oxide release, which is associated with neuroinflammation. The research found that CBD and ARBs, when administered alone, reduced nitric oxide synthesis, but when combined, they had a synergistic inhibitory effect. Additionally, CBD showed anti-inflammatory effects when combined with the known anti-inflammatory agent dimethyl fumarate. These findings suggest the potential of combining CBD with ARBs or other agents for the treatment of neuroinflammation. [Extracted from the article]

Researchers at Shandong First Medical University in China have published new data on the pharmacology of ELABELA (ELA), a novel endogenous ligand of the angiotensin receptor APJ. ELA is highly expressed in human embryonic, cardiac, and renal tissues and is involved in various biological functions, including embryonic development, blood circulation regulation, and maintaining body fluid homeostasis. The researchers found that ELA is closely related to the occurrence and development of kidney-related diseases such as acute kidney injury, hypertensive kidney damage, diabetic nephropathy, and renal tumors. Understanding the physiological role of ELA and its mechanism of action in kidney diseases could lead to new targets and directions for clinical treatment. [Extracted from the article]

For more information on this research see: Comparative Efficacy And Acceptability of Different Antihypertensive Drug Classes For Cardiovascular Disease Prevention: A Systematic Review And Network Meta-analysis. Keywords: Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Antihypertensives; Autacoids; Biological Factors; CCB Therapy; Calcium Channel Blocking Agents; Cardiology; Cardiovascular; Cardiovascular Diseases and Conditions; Cardiovascular Research; Drugs and Therapies; Health and Medicine; Membrane Proteins; Peptide Receptors; Pharmaceuticals; Risk and Prevention EN Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Antihypertensives Autacoids Biological Factors CCB Therapy Calcium Channel Blocking Agents Cardiology Cardiovascular Cardiovascular Diseases and Conditions Cardiovascular Research Drugs and Therapies Health and Medicine Membrane Proteins Peptide Receptors Pharmaceuticals Risk and Prevention 1032 1032 1 11/06/23 20231110 NES 231110 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on cardiovascular diseases and conditions have been published. Our aim was to assess the efficacy for cardiovascular disease prevention as well as acceptability across all antihypertensive drug classes.". [Extracted from the article]

Keywords: Al Jubail; Saudi Arabia; Asia; Angiotensin II Inhibitors; Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Autacoids; Biological Factors; Cardiovascular Agents; Drugs and Therapies; G-Protein-Coupled Receptors; Health and Medicine; Membrane Proteins; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptide Receptors; Peptides; Pharmaceuticals; Proteins; Valsartan Therapy EN Al Jubail Saudi Arabia Asia Angiotensin II Inhibitors Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Autacoids Biological Factors Cardiovascular Agents Drugs and Therapies G-Protein-Coupled Receptors Health and Medicine Membrane Proteins Neuropeptide Receptors Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptide Receptors Peptides Pharmaceuticals Proteins Valsartan Therapy 1675 1675 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Angiotensin II Inhibitors have been published. Al Jubail, Saudi Arabia, Asia, Angiotensin II Inhibitors, Angiotensin II Receptor Antagonist, Angiotensin Receptors, Angiotensins, Autacoids, Biological Factors, Cardiovascular Agents, Drugs and Therapies, G-Protein-Coupled Receptors, Health and Medicine, Membrane Proteins, Neuropeptide Receptors, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptide Receptors, Peptides, Pharmaceuticals, Proteins, Valsartan Therapy. [Extracted from the article]

Keywords: Angiotensin II; Angiotensin Receptors; Angiotensins; Autacoids; Biological Factors; Cancer; Cardiovascular Diseases and Conditions; Colon Cancer; Colorectal Research; G-Protein-Coupled Receptors; Gastroenterology; Health and Medicine; Membrane Proteins; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptide Receptors; Peptides; Proteins; Risk and Prevention EN Angiotensin II Angiotensin Receptors Angiotensins Autacoids Biological Factors Cancer Cardiovascular Diseases and Conditions Colon Cancer Colorectal Research G-Protein-Coupled Receptors Gastroenterology Health and Medicine Membrane Proteins Neuropeptide Receptors Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptide Receptors Peptides Proteins Risk and Prevention 413 413 1 09/25/23 20230929 NES 230929 2023 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in colon cancer. Angiotensin II contributes greatly to CVD pathogenesis, and Angiotensin II receptor blockers (ARBs) constitute a mainstay in hypertension and CVD management.". [Extracted from the article]

Park Ridge, State:Illinois, United States, North and Central America, Adverse Drug Reactions, Angiotensin II Inhibitors, Angiotensin II Receptor Antagonist, Angiotensin Receptors, Angiotensins, Autacoids, Biological Factors, Cardiovascular Agents, Drugs and Therapies, G-Protein-Coupled Receptors, Government Agencies Offices and Entities, Health and Medicine, Legal Issues, Membrane Proteins, Neuropeptide Receptors, Neuropeptides, Oligopeptides, Olmesartan Therapy, Peptide Hormones, Peptide Proteins, Peptide Receptors, Peptides, Pharmaceuticals, Proteins, Regulatory Agencies Keywords: Park Ridge; State:Illinois; United States; North and Central America; Adverse Drug Reactions; Angiotensin II Inhibitors; Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Autacoids; Biological Factors; Cardiovascular Agents; Drugs and Therapies; G-Protein-Coupled Receptors; Government Agencies Offices and Entities; Health and Medicine; Legal Issues; Membrane Proteins; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Olmesartan Therapy; Peptide Hormones; Peptide Proteins; Peptide Receptors; Peptides; Pharmaceuticals; Proteins; Regulatory Agencies EN Park Ridge State:Illinois United States North and Central America Adverse Drug Reactions Angiotensin II Inhibitors Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Autacoids Biological Factors Cardiovascular Agents Drugs and Therapies G-Protein-Coupled Receptors Government Agencies Offices and Entities Health and Medicine Legal Issues Membrane Proteins Neuropeptide Receptors Neuropeptides Oligopeptides Olmesartan Therapy Peptide Hormones Peptide Proteins Peptide Receptors Peptides Pharmaceuticals Proteins Regulatory Agencies 1399 1399 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Angiotensin II Receptor Antagonist. [Extracted from the article]

Keywords for this news article include: West Virginia University Heart and Vascular Institute, Morgantown, West Virginia, United States, North and Central America, Antihypertensives, Cancer, Oncology, Autacoids, Hypertension, Membrane Proteins, Peptide Receptors, Biological Factors, Drugs and Therapies, Health and Medicine, Angiotensin Receptors, Angiotensin II Receptor Antagonist, Cardiovascular Diseases and Conditions. Angiotensin II Receptor Antagonist, Angiotensin Receptors, Angiotensins, Antihypertensives, Autacoids, Biological Factors, Cancer, Cardiovascular Diseases and Conditions, Drugs and Therapies, Health and Medicine, Hypertension, Membrane Proteins, Oncology, Peptide Receptors Keywords: Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Antihypertensives; Autacoids; Biological Factors; Cancer; Cardiovascular Diseases and Conditions; Drugs and Therapies; Health and Medicine; Hypertension; Membrane Proteins; Oncology; Peptide Receptors EN Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Antihypertensives Autacoids Biological Factors Cancer Cardiovascular Diseases and Conditions Drugs and Therapies Health and Medicine Hypertension Membrane Proteins Oncology Peptide Receptors 383 383 1 09/11/23 20230915 NES 230915 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on hypertension have been published. [Extracted from the article]

Belo Horizonte, Brazil, South America, Angiotensin II Inhibitors, Angiotensin II Receptor Antagonist, Angiotensin Receptors, Angiotensins, Antiarrhythmic Agents, Antihypertensives, Autacoids, Biological Factors, Boron Nitride, Cardiovascular Agents, Chemicals, Drugs and Therapies, Emerging Technologies, G-Protein-Coupled Receptors, Health and Medicine, Losartan Therapy, Membrane Proteins, Nanotechnology, Nanotubes, Neuropeptide Receptors, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptide Receptors, Peptides, Pharmaceuticals, Proteins, Boron Nitride Nanotube Keywords: Belo Horizonte; Brazil; South America; Angiotensin II Inhibitors; Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Antiarrhythmic Agents; Antihypertensives; Autacoids; Biological Factors; Boron Nitride; Boron Nitride Nanotube; Cardiovascular Agents; Chemicals; Drugs and Therapies; Emerging Technologies; G-Protein-Coupled Receptors; Health and Medicine; Losartan Therapy; Membrane Proteins; Nanotechnology; Nanotubes; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptide Receptors; Peptides; Pharmaceuticals; Proteins EN Belo Horizonte Brazil South America Angiotensin II Inhibitors Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Antiarrhythmic Agents Antihypertensives Autacoids Biological Factors Boron Nitride Boron Nitride Nanotube Cardiovascular Agents Chemicals Drugs and Therapies Emerging Technologies G-Protein-Coupled Receptors Health and Medicine Losartan Therapy Membrane Proteins Nanotechnology Nanotubes Neuropeptide Receptors Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptide Receptors Peptides Pharmaceuticals Proteins 2084 2084 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Nanotechnology - Nanotubes is now available. [Extracted from the article]

Keywords: Omaha; State:Nebraska; United States; North and Central America; Angiotensins; Autacoids; Biological Factors; Drugs and Therapies; Endothelins; Health and Medicine; Intercellular Signaling Peptides and Proteins; Kidney; Nephrology; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Proteins EN Omaha State:Nebraska United States North and Central America Angiotensins Autacoids Biological Factors Drugs and Therapies Endothelins Health and Medicine Intercellular Signaling Peptides and Proteins Kidney Nephrology Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Proteins 2297 2297 1 07/03/23 20230707 NES 230707 2023 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Peptide Proteins - Peptide Hormones are discussed in a new report. Omaha, State:Nebraska, United States, North and Central America, Angiotensins, Autacoids, Biological Factors, Drugs and Therapies, Endothelins, Health and Medicine, Intercellular Signaling Peptides and Proteins, Kidney, Nephrology, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Pharmaceuticals, Proteins. [Extracted from the article]

According to news reporting out of Hangzhou, People's Republic of China, by NewsRx editors, research stated, "The peptide hormone angiotensin II regulates blood pressure mainly through the type 1 angiotensin II receptor AT(1)R and its downstream signaling proteins G(q) and beta-arrestin. Keywords: Hangzhou; People's Republic of China; Asia; Angiotensin II; Angiotensin Receptors; Angiotensins; Arrestins; Autacoids; Biological Factors; Drugs and Therapies; Eye Proteins; G-Protein-Coupled Receptors; Health and Medicine; Immunology; Membrane Proteins; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptide Receptors; Peptides; Proteins; Surface Antigens; Type 1 Receptor EN Hangzhou People's Republic of China Asia Angiotensin II Angiotensin Receptors Angiotensins Arrestins Autacoids Biological Factors Drugs and Therapies Eye Proteins G-Protein-Coupled Receptors Health and Medicine Immunology Membrane Proteins Neuropeptide Receptors Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptide Receptors Peptides Proteins Surface Antigens Type 1 Receptor 568 568 1 05/22/23 20230526 NES 230526 2023 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Proteins - Eye Proteins. [Extracted from the article]

Keywords: Angiotensin II; Angiotensin II Inhibitors; Angiotensin II Receptor Antagonist; Angiotensin II Therapy; Angiotensins; Antiarrhythmic Agents; Antihypertensives; Autacoids; Biological Factors; Cancer; Carcinomas; Cardiovascular Agents; Drugs and Therapies; Gastroenterology; Giapreza Therapy; Health and Medicine; Liver Cancer; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis; Losartan Therapy; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Oncology; Peptide Hormones; Peptide Proteins; Peptides; Pharmaceuticals; Proteins; Vasopressors EN Angiotensin II Angiotensin II Inhibitors Angiotensin II Receptor Antagonist Angiotensin II Therapy Angiotensins Antiarrhythmic Agents Antihypertensives Autacoids Biological Factors Cancer Carcinomas Cardiovascular Agents Drugs and Therapies Gastroenterology Giapreza Therapy Health and Medicine Liver Cancer Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis Losartan Therapy Nerve Tissue Proteins Neuropeptides Oligopeptides Oncology Peptide Hormones Peptide Proteins Peptides Pharmaceuticals Proteins Vasopressors 1156 1156 1 05/15/23 20230519 NES 230519 2023 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in liver fibrosis. For more information on this research see: Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. [Extracted from the article]

Keywords: Toulouse; France; Europe; Angiotensin II Inhibitors; Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Autacoids; Biological Factors; Biological Tumor Markers; CD Antigens; Cardiovascular Agents; Drugs and Therapies; Enzymes and Coenzymes; G-Protein-Coupled Receptors; Health and Medicine; Immunology; Membrane Proteins; Metalloendopeptidases; Neoplasm Antigens; Neprilysin; Neuropeptide Receptors; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Hydrolases; Peptide Proteins; Peptide Receptors; Peptides; Pharmaceuticals; Proteins; Valsartan Therapy EN Toulouse France Europe Angiotensin II Inhibitors Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Autacoids Biological Factors Biological Tumor Markers CD Antigens Cardiovascular Agents Drugs and Therapies Enzymes and Coenzymes G-Protein-Coupled Receptors Health and Medicine Immunology Membrane Proteins Metalloendopeptidases Neoplasm Antigens Neprilysin Neuropeptide Receptors Neuropeptides Oligopeptides Peptide Hormones Peptide Hydrolases Peptide Proteins Peptide Receptors Peptides Pharmaceuticals Proteins Valsartan Therapy 1789 1789 1 04/24/23 20230428 NES 230428 2023 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Drugs and Therapies - Angiotensin II Inhibitors is the subject of a report. [Extracted from the article]

Boston, State:Massachusetts, United States, North and Central America, Angiotensin II, Angiotensins, Autacoids, Biological Factors, Cardiovascular Agents, Drugs and Therapies, Giapreza Therapy, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Proteins, Vasopressors Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Angiotensin II, Angiotensins, Autacoids, Biological Factors, Cardiovascular Agents, Drugs and Therapies, Giapreza Therapy, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Proteins, Vasopressors, Brigham and Women's Hospital. Keywords: Boston; State:Massachusetts; United States; North and Central America; Angiotensin II; Angiotensins; Autacoids; Biological Factors; Cardiovascular Agents; Drugs and Therapies; Giapreza Therapy; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Proteins; Vasopressors EN Boston State:Massachusetts United States North and Central America Angiotensin II Angiotensins Autacoids Biological Factors Cardiovascular Agents Drugs and Therapies Giapreza Therapy Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Proteins Vasopressors 1672 1672 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Cardiovascular Agents have been published. [Extracted from the article]

For more information on this research see: Effectiveness and Safety of Fixed-dose Combination of Perindopril/Amlodipine/Indapamide, and Telmisartan/Amlodipine/Chlorthalidone in Grade 2 Hypertensive Patients at High Cardiovascular Risk: A Real-world Observational Study. Keywords: Amides; Angiotensin II Receptor Antagonist; Angiotensin Receptors; Angiotensins; Autacoids; Benzophenones; Biological Factors; Blood Pressure; Cardiology; Cardiovascular; Cardiovascular Research; Chlorthalidone; Drugs and Therapies; Health and Medicine; Hemodynamics; Indapamide; Membrane Proteins; Peptide Receptors; Phthalic Acids; Phthalimides; Sulfonamides EN Amides Angiotensin II Receptor Antagonist Angiotensin Receptors Angiotensins Autacoids Benzophenones Biological Factors Blood Pressure Cardiology Cardiovascular Cardiovascular Research Chlorthalidone Drugs and Therapies Health and Medicine Hemodynamics Indapamide Membrane Proteins Peptide Receptors Phthalic Acids Phthalimides Sulfonamides 281 281 1 03/24/23 20230224 NES 230224 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on angiotensin II receptor antagonist are discussed in a new report. [Extracted from the article]

Cardiovascular Diseases and Conditions - Reperfusion Injury Investigators discuss new findings in reperfusion injury. A major cardiovascular ROS source in this setting is theactivation of multiple NADPH oxidases, which could result via theoccupancy of type 1 angiotensin II receptors (AT1R); hence, the reninangiotensin system (RAS) is associated with the generation of ROS duringreperfusion. [Extracted from the article]